Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2019-03-25 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2019年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a 2019 first quarter earnings forecast (业绩预告) for the period January 1 to March 31, 2019. It provides estimated financial performance figures and states that the forecast is unaudited and preliminary. It explicitly mentions that detailed actual data will be disclosed in the 2019 first quarter report. The document is short (900 characters) and is a forward-looking earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly/periodical financial results with key highlights only. Q1 2019
2019-03-25 Chinese
2018年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2018年度监事会工作报告" which translates to "2018 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight of financial reports, compliance with laws and regulations, internal controls, and plans for 2019. It references the audit report issued by an accounting firm but does not itself contain the audit report or full financial statements. The document is a formal report from the supervisory board summarizing their oversight and work during the year, which aligns with a Management Report or Supervisory Board Report rather than a full Annual Report (10-K) or Audit Report (AR). It is not a short announcement or certification but a substantive report on supervisory activities and opinions on company operations and financials. Therefore, the best fitting category is Management Reports (MDA). The document length (3379 characters) is sufficient for a detailed report but not a full annual report. Hence, classification as MDA is appropriate with high confidence.
2019-03-25 Chinese
第二届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. It details the approval of various reports and proposals related to the 2018 fiscal year, including the 2018 Supervisory Board Work Report, changes in accounting policies, the 2018 Annual Report and its summary, the 2018 financial statements audited by an accounting firm, the 2018 profit distribution plan, a special report on the use of raised funds, an internal control self-assessment report, and the appointment of the 2019 audit firm. The document states that these reports and proposals will be submitted to the 2018 Annual General Meeting for approval. The document itself does not contain the full annual report or detailed financial statements but rather summarizes the resolutions passed by the Supervisory Board and refers to the full reports published elsewhere on the designated disclosure website. The document length is 2917 characters, which is relatively short and consistent with an announcement of meeting resolutions rather than the full annual report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of Supervisory Board meeting resolutions and approvals related to the annual report and other financial matters, but it is not the full Annual Report (10-K) itself.
2019-03-25 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the progress and details of using idle raised funds for cash management, including information about the purchase and redemption of financial products, investment risks, approvals, and related procedures. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement about financing activities related to the use of raised funds, specifically cash management of idle funds. The document length is about 5090 characters, which is consistent with a detailed announcement but not a full annual or interim report. The content focuses on capital management and investment of idle funds, which fits the category of Capital/Financing Update (CAP).
2019-03-15 Chinese
关于持股5%以上股东部分股份提前解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the early release of pledged shares by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, the number of shares released from pledge, pledge start and end dates, and related information. There is no financial data, earnings information, or management discussion. The document is short (1160 characters) and serves as a regulatory disclosure about share pledge status. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership or related shareholding events such as pledges or releases.
2019-03-08 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Xiamen Aide Biomedical Technology Co., Ltd. regarding the progress of using idle raised funds for cash management. It details the company's use of temporarily idle raised funds to purchase low-risk financial products, including amounts, terms, and expected yields. The document includes tables of financial products purchased and redeemed, risk control measures, and approvals from the board and shareholders. It is an update on financing activities related to the use of raised funds, not a full financial report or earnings release. The document is about cash management of idle raised funds, which fits the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive financial data about financing activities, not just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2019-03-05 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.